Core Insights - Ichor Holdings, Ltd. reported fourth quarter and fiscal year 2025 financial results, indicating a favorable alignment with earlier expectations and a positive outlook for fiscal 2026 driven by strengthening customer demand [1][2][3]. Financial Performance Fourth Quarter 2025 Highlights - Revenue for Q4 2025 was $223.6 million, a decrease from $239.3 million in Q3 2025 and $233.3 million in Q4 2024 [2][6]. - The gross margin was 9.4% on a GAAP basis and 11.7% on a non-GAAP basis, compared to 4.6% and 12.1% respectively in Q3 2025 [1][6]. - The net loss for Q4 2025 was $(15.96) million, with a diluted EPS of $(0.46), improving from a net loss of $(22.85) million and diluted EPS of $(0.67) in Q3 2025 [2][6]. Fiscal Year 2025 Highlights - Total revenue for FY 2025 reached $947.7 million, representing an 11.6% increase from $849.0 million in FY 2024 [3][6]. - The net loss for FY 2025 was $(52.8) million, with a diluted EPS of $(1.54), compared to a net loss of $(20.8) million and diluted EPS of $(0.64) in FY 2024 [3][6]. Non-GAAP Financial Results - For Q4 2025, non-GAAP net income was $0.3 million, with a non-GAAP diluted EPS of $0.01, down from $2.3 million and $2.8 million in Q3 2025 and Q4 2024 respectively [4][6]. - For FY 2025, non-GAAP net income was $7.9 million, with a non-GAAP diluted EPS of $0.23, compared to $5.9 million and $0.18 in FY 2024 [4][6]. Cash Flow and Balance Sheet - At the end of Q4 2025, cash and cash equivalents totaled $98.3 million, an increase of $5.8 million from the previous quarter but a decrease of $10.4 million from the prior year [8][9]. - Cash provided by operating activities for Q4 2025 was $9.2 million, driven by net cash from operations despite a net loss of $(15.96) million [10][9]. Outlook for First Quarter 2026 - The company expects Q1 2026 revenue to range from $240 million to $260 million, with GAAP diluted EPS projected between $(0.10) and $0.02, and non-GAAP diluted EPS between $0.08 and $0.16 [5][6].

Kulicke & Soffa While these forward-looking statements represent our judgments and future expectations concerning our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, the factors listed or discussed in our 2025 Annual Report on Form 10-K and our other filings with the Securities and Exchange Commission. Kulicke and Soffa Industries, Inc. is under no obl ...

Core Insights - AbbVie reported strong financial results for the fourth quarter and full year of 2025, with a notable increase in net revenues and adjusted diluted EPS guidance for 2026 [1] Financial Performance - Fourth-quarter net revenues reached $16.618 billion, marking a 10.0% increase on a reported basis and 9.5% on an operational basis [1] - Full-year net revenues totaled $61.160 billion, an increase of 8.6% on a reported basis and 8.5% on an operational basis [1] - Fourth-quarter diluted EPS was $1.02 on a GAAP basis, while adjusted diluted EPS was $2.71, reflecting an unfavorable impact of $0.71 per share from acquired IPR&D and milestones expense [1] Portfolio Performance - The immunology portfolio generated global net revenues of $30.406 billion for the full year, an increase of 14.0% on a reported basis [1] - The neuroscience portfolio saw a 19.6% increase in global net revenues, totaling $10.767 billion for the full year [1] - The oncology portfolio reported full-year global net revenues of $6.655 billion, a slight increase of 1.5% on a reported basis [1] - The aesthetics portfolio experienced a decline, with full-year global net revenues of $4.860 billion, down 6.1% on a reported basis [1] Recent Developments - AbbVie announced the acquisition of a device manufacturing facility from West Pharmaceutical Services to enhance production capabilities for immunology and neuroscience medicines [1] - An exclusive licensing agreement was established with RemeGen for the development of a novel bispecific antibody, RC148, aimed at treating advanced solid tumors [1] - AbbVie received FDA approval for Epkinly in combination with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma [1] - The company submitted applications for expanded use of Aquipta for migraine treatment and for Rinvoq in treating non-segmental vitiligo [1] 2026 Outlook - AbbVie provided adjusted diluted EPS guidance for 2026 in the range of $14.37 to $14.57, excluding any unfavorable impacts from acquired IPR&D and milestones [1]

Core Insights - Kulicke and Soffa Industries, Inc. reported fourth quarter fiscal 2025 net revenue of $177.6 million, a decrease from $181.3 million in the same quarter of fiscal 2024, and net income of $6.4 million, down from $12.1 million year-over-year [1][9] - The company anticipates first quarter fiscal 2026 net revenue to be approximately $190 million, with GAAP diluted EPS expected around $0.18 and non-GAAP diluted EPS around $0.33 [2][17] Financial Highlights - **Fourth Quarter Fiscal 2025 Results**: - Net revenue: $177.6 million, down from $181.3 million in Q4 2024 [1] - GAAP diluted EPS: $0.12, compared to $0.22 in Q4 2024 [1] - Non-GAAP diluted EPS: $0.28, down from $0.34 in Q4 2024 [1] - **Fiscal Year 2025 Overview**: - Total net revenue for the fiscal year was $654.1 million, with a gross margin of 42.5% [9] - Net income for the fiscal year was $0.2 million, or $0.004 per fully diluted share [9] Operational Insights - The company is focusing on multiple technology engagements and is optimistic about improving end market dynamics and order activity [2] - Global operations and supply chain teams are preparing for increased customer demand in the upcoming quarters [2] Cash Flow and Share Repurchase - GAAP cash flow from operations for Q4 2025 was $7.4 million, with adjusted free cash flow of $4.4 million [9] - The company repurchased 0.5 million shares of common stock at a cost of $16.7 million during the quarter [9] Future Outlook - The company expects first quarter fiscal 2026 net revenue to be approximately $190 million, with a variance of +/- $10 million [2][17] - GAAP diluted EPS is projected to be around $0.18, while non-GAAP diluted EPS is expected to be approximately $0.33 [2][17]

Q3F25 Financial Performance - Revenue for Q3F25 was $148.4 million, a decrease of 8.4% quarter-over-quarter [9, 16] - Net loss for Q3F25 was $(3.3) million, while non-GAAP net income was $3.8 million [9] - EPS was $(0.06), and non-GAAP EPS was $0.07 [9] - Gross margin was 46.7%, an increase of 2180 bps quarter-over-quarter [18] - Operating expenses were $75.3 million, a decrease of $(49.7) million quarter-over-quarter [18] Outlook for Q4F25 - The company anticipates revenue of $170 million, with a potential variance of +/- $10 million [21] - The company expects operating expenses of $68.0 million, with a potential variance of +/- 2% [21] - The company projects diluted EPS of $0.22, with a potential variance of +/- 10% [21] Strategic Focus and Market Dynamics - The company is internally focused on efficiency, customer engagement, and new product execution [11] - Macro order hesitation, primarily affecting Auto/Industrial demand, contributed to the sequential revenue change [11] - Technology and capacity-related order activity are driving General Semi & Memory recovery [11] - Vertical Wire is positioned well for mobile-HBM, and new Wedge solutions are enabling more capable & efficient Power-Semi [11]